Oncology

IDEAYA Biosciences announced stock option grants to a new employee. The company awarded 95,600 shares at $22.29 per share under its 2023 plan, aiming to attract talent. Options vest over four years, with 25% vesting after the first year. IDEAYA, a precision medicine oncology company, focuses on targeted therapies based on molecular diagnostics and synthetic lethality approaches.

BioNTech’s Q1 2025 revenue was €182.8 million, with a net loss of €415.8 million. The company is focusing on its oncology pipeline, including BNT327 and mRNA cancer immunotherapies. It’s also preparing for a variant-adapted COVID-19 vaccine for the 2025/2026 season and confirmed its full-year 2025 financial guidance.